Registered outcomes19

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 19 of 19

List	Outcome	Time frame	Description
Primary	Rate of extubation failure	48 hours	Reintubation. The discretion of the attending physician.
Secondary	Frequency of apneas	48 hours	Respiratory failure of 15-20 seconds or shorter duration associated with bradycardia or desaturation.
Secondary	Change in the mean heart rate	72 hours	Mean heart rate measured 24 hours before and 48 hours after intervention.
Secondary	Tachycardia	72 hours	The time interval when the heart rate \>200 (min) during one day (1440 min) in percentage.
Secondary	Volume of gastric residuals	72 hours	Gastric residuals measured 24 hours before and 48 hours after intervention.
Secondary	Reduction/Cessation of feeding	48hours	48 hours after intervention.
Secondary	Change in mean arterial blood pressure	48 hours	Mean blood pressure measured 24 hours before and after intervention measured with non-invasive methods.
Secondary	Mechanical ventilation (MV) days	At discharge from participating centres, an average of one month.	MV days during the length of hospital stay
Secondary	Non-invasive ventilation (NIV) days	At discharge from participating centres, an average of one month.	NIV days during the length of hospital stay
Secondary	Rate of necrotizing enterocolitis	At discharge from participating centres, an average of one month.	Development of necrotizing enterocolitis according to Bell stages.
Secondary	Rate of Intraventricular hemorrhage	At discharge from participating centres, an average of one month.	Development or progression of intraventricular hemorrhage according to Papile stages diagnosed with cranial ultrasound.
Secondary	Rate of periventricular leukomalacia	At discharge from participating centres, an average of one month.	Development of periventricular leukomalacia, seen on cranial ultrasound.
Secondary	Rate of late-onset sepsis	At discharge from participating centres, an average of one month.	Culture proven sepsis after the first 72 hours of life.
Secondary	Rate of patent ductus arteriosus	At discharge from participating centres, an average of one month.	Pharmacological or surgical treatment was required.
Secondary	Rate of bronchopulmonary dysplasia	36th postmenstrual age	Diagnosis of bronchopulmonary dysplasia.
Secondary	Rate of death before discharge	At discharge from participating centres, an average of one month.
Secondary	Required oxygen concentration	24 hours	Required oxygen concentration before and after the intervention.
Secondary	Long term neurodevelopmental outcome	At 2 years of corrected age	Measured by Bayley score. The standardized mean score is 100 (SD 15), with scores lower than 85 indicating mild impairment, and lower than 70 indicating moderate or severe impairment.
Secondary	Severity of sensoric or motoric impairment	At 2 years of corrected age	Hearing or visual impairment, and cerebral palsy

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT06401083/registered

API reference For AI assistants